PCSK9 Battleground Hits The Court, Not The Market, After Amgen Sues
This article was originally published in The Pink Sheet Daily
Executive Summary
A month after filing a BLA for its cholesterol-lowering PCSK9 inhibitor, Amgen sues partners Sanofi and Regeneron claiming infringement of three patents that describe monoclonal antibodies to PCSK9.